August 2022: Bukaannada qaangaarka ah ee qaba kansarka sambabada unugyada yaryar ee dheef-shiid kiimikaadka (NSCLC) kuwaas oo burooyinkoodu ay leeyihiin isbeddel taasoo keentay kala-guurka mesenchymal-epithelial (MET) exon 14, sida lagu ogaaday baaritaanka FDA-ansixisay, Maamulka Cuntada iyo Dawooyinka ayaa siiyay capmatinib (Tabrecta). , Novartis Pharmaceuticals Corp.) oggolaanshaha joogtada ah.
Iyada oo ku saleysan heerka jawaabta guud ee bilowga ah iyo muddada jawaabta ee tijaabada GEOMETRY mono-1 (NCT02414139), xarun badan, aan kala sooc lahayn, calaamad furan, cilmi-baaris kooxeedyo badan, capmatinib ayaa hore loo siiyay oggolaan degdeg ah isla tilmaanta May 6, 2020. Iyada oo ku saleysan xogta laga helay 63 bukaan oo dheeraad ah iyo 22 bilood oo dheeri ah oo dabagal ah si loo qiimeeyo adkeysiga jawaabta loona xaqiijiyo faa'iidada daweynta, beddelka ogolaanshaha joogtada ah ayaa la sameeyay.
160 bukaan oo qaba NSCLC heersare ah oo leh isbeddel ku yimid exon 14 ee MET ayaa muujiyay waxtarka. Bukaan-socodka ayaa helay capmatinib 400 mg laba jeer maalintii ilaa cudurkoodu ka sii socdo ama waxyeellooyinka ay noqdeen kuwo aan loo dulqaadan karin.
Guddiga Dib-u-eegista Madax-bannaan ee Indho-la'aanta ah ayaa go'aamiyay ORR iyo muddada jawaabta (DOR) inay yihiin tallaabooyinka waxtarka weyn (BIRC). 60 qof oo aan waligood daawayn helin waxay lahaayeen ORR 68% (95% CI: 55, 80) iyo DOR ah 16.6 bilood (95% CI: 8.4, 22.1). ORR wuxuu ahaa 44% (95% CI: 34, 54) oo ka mid ah 100 bukaan oo hore loo daaweeyay, DOR waxay ahayd 9.7 bilood (95% CI: 5.6, 13).
The patients’ average age was 71 years (48 to 90). The following specific demographics were reported: 61% female, 77% White, 61% never smoked, 83% had adenocarcinoma, and 16% had metastases to the central nervous system. 81% of patients who had previously had treatment had only gotten one line of systemic therapy; 16% had received two; and 3% had received three. 86% of patients who had previously had treatment had platinum-based chemotherapy.
Bukaanku waxay la kulmeen edoema, lallabbo, xanuun murqo-xanuun, daal, matag, dyspnea, qufac, iyo rabitaanka cuntada oo hoos u dhacay inta badan (20%).
Capmatinib waa in afka laga qaataa laba jeer maalintii qiyaasta 400 mg, cunto la'aan ama la'aan.
Eeg macluumaadka daawaynta oo dhamaystiran ee Tabrecta
